Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome.
Human Molecular Genetics. 2000-12-01; 9(20): 3101-3110
Read on PubMed
1. Drug Des Devel Ther. 2018 Jul 24;12:2301-2309. doi: 10.2147/DDDT.S165171.
Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male
Choi Y(1), Lee S(1), Jang IJ(1), Yu KS(1).
(1)Department of Clinical Pharmacology and Therapeutics, Seoul National
University College of Medicine and Hospital, Seoul, Republic of Korea,
Introduction: Major cardiovascular risk factors, including hypertension and
dyslipidemia, are often comorbidities, frequently leading to concurrent
prescription of angiotensin receptor blockers and
3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). The study’s
objective was to evaluate the effect of coadministration of fimasartan and
atorvastatin on their pharmacokinetics (PKs).
Subjects and methods: In a randomized, open-label, three-period, six-sequence,
crossover, multiple-dose study, 36 healthy subjects received 120 mg fimasartan,
40 mg atorvastatin, or both (based on their assigned sequence) once daily for 7
days in each period, with a 7-day washout between periods. Blood samples for the
PK analysis of fimasartan, atorvastatin, and the 2-hydroxy atorvastatin
metabolite were collected up to 48 h after the last dose.
Results: The coadministration of fimasartan and atorvastatin was well tolerated
and led to an increase in the peak concentration and area under the
concentration-time curve at steady state of fimasartan by 2.18-fold (95%
confidence interval [CI], 1.79-2.65) and 1.35-fold (95% CI, 1.26-1.43) and those
of atorvastatin increased by 1.82-fold (95% CI, 1.51-2.18) and 1.12-fold (95% CI,
Conclusion: Coadministration increased the systemic exposures of fimasartan and
atorvastatin, but the clinical significance of this finding needs to be evaluated
with respect to exposure responses and clinical outcomes.
Conflict of interest statement: Disclosure The authors report no conflicts of
interest in this work.